Arterial disease in chronic kidney disease

Heart

Volumn 99, Issue 6, 2013, Pages 365-372

  Moody, William E ^a   Edwards, Nicola C ^a   Chue, Colin D ^a   Ferro, Charles J ^a   Townend, Jonathan N ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; ANTIHYPERTENSIVE AGENT; CALCIUM CARBONATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANTHANUM; MINERALOCORTICOID ANTAGONIST; PERINDOPRIL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; PRAVASTATIN; SEVELAMER; SIMVASTATIN; SPIRONOLACTONE; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ARTERY CALCIFICATION; ARTERY COMPLIANCE; ARTERY DISEASE; ATHEROMA; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; METABOLIC BONE DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK REDUCTION;

ARTERIAL OCCLUSIVE DISEASES; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; HUMANS; INCIDENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; WORLD HEALTH;

EID: 84874106651     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302818     Document Type: Review

References (97)

1. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-15. (Pubitemid 29297538)
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-19. (Pubitemid 28527268)
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
4. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47. (Pubitemid 350074801)
5. Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011;26:379-85.
6. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
7. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-19. (Pubitemid 30004750)
8. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
9. Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004;66:1310-14. (Pubitemid 39302630)
10. Van Biesen W, De Bacquer D, et al. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007;28:478-83. (Pubitemid 47343557)
11. Mafham M, Emberson J, Landray MJ, et al. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One 2011;6:e25920.
12. Cerasola G, Cottone S, Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens 2010;28:2357-69.
13. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004;110:32-5. (Pubitemid 38880131)
14. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005;112:969-75. (Pubitemid 41170264)
15. Coresh J, Longenecker JC, Miller ER III, et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9(12 Suppl):S24-30.
16. Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808. (Pubitemid 36315558)
17. US Renal Data System (USRDS). Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011.
18. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-95. (Pubitemid 41725146)
19. Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005;67:217-26. (Pubitemid 40019243)
20. Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006;69:1839-45. (Pubitemid 43739213)
21. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
22. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61. (Pubitemid 350190755)
23. Edwards NC, Steeds RP, Ferro CJ, et al. The treatment of coronary artery disease in patients with chronic kidney disease. QJM 2006;99:723-36. (Pubitemid 44688406)
24. Schwarz U, Buzello M, Ritz E, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-23. (Pubitemid 30064276)
25. Leskinen Y, Lehtimaki T, Loimaala A, et al. Carotid atherosclerosis in chronic renal failure-the central role of increased plaque burden. Atherosclerosis 2003;171:295-302. (Pubitemid 37486082)
26. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380:807-14.
27. MacWalter RS, Wong SY, Wong KY, et al. Does renal dysfunction predict mortality after acute stroke? A 7-year follow-up study. Stroke 2002;33:1630-5. (Pubitemid 34619970)
28. Hanna EB, Chen AY, Roe MT, et al. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011;4:1002-8.
29. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 2011;4:1011-19.
30. Kumai Y, Kamouchi M, Hata J, et al. Proteinuria and clinical outcomes after ischemic stroke. Neurology 2012;78:1909-15.
31. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998;339:799-805. (Pubitemid 28447453)
32. Thambyrajah J, Landray MJ, McGlynn FJ, et al. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000;83:205-9. (Pubitemid 30305552)
33. Stam F, van Guldener C, Becker A, et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006;17:537-45.
34. Bolton CH, Downs LG, Victory JG, et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001;16:1189-97. (Pubitemid 32547374)
35. Lilitkarntakul P, Dhaun N, Melville V, et al. Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 2011;216:217-25.
36. Moody WE, Edwards NC, Madhani M, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 2012;223:86-94.
37. Yilmaz MI, Axelsson J, Sonmez A, et al. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc Nephrol 2009;4:535-41.
38. Yilmaz MI, Sonmez A, Saglam M, et al. Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? Nephrol Dial Transplant 2010;25:3250-6.
39. Moody WE, Ferro CJ, Chue CD, et al. Invite all donors to participate in follow-up studies. BMJ 2012;344:e2724.
40. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010;303:959-66.
41. Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;156:445-59.
42. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.
43. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48. (Pubitemid 41058323)
44. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63. (Pubitemid 39297976)
45. Ninomiya T, Perkovic V, Gallagher M, et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 2008;73:963-70. (Pubitemid 351458323)
46. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36. (Pubitemid 32322240)
47. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001;32:454-60. (Pubitemid 32155234)
48. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension. A systematic review. Hypertension 2009;54:1328-36.
49. Schmitt M, Avolio A, Qasem A, et al. Basal NO locally modulates human iliac artery function in vivo. Hypertension 2005;46:227-31. (Pubitemid 40946519)
50. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-92. (Pubitemid 32183805)
51. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9. (Pubitemid 29218240)
52. Blacher J, Pannier B, Guerin AP, et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998;32:570-4. (Pubitemid 28429151)
53. Edwards NC, Ferro CJ, Townend JN, et al. Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart 2008;94:1038-43. (Pubitemid 352039887)
54. Briet M, Bozec E, Laurent S, et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006;69:350-7. (Pubitemid 43323087)
55. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. Hypertension 2009;54:375-83.
56. Davies JE, Parker KH, Francis DP, et al. What is the role of the aorta in directing coronary blood flow? Heart 2008;94:1545-7.
57. London G, Guerin A, Pannier B, et al. Increased systolic pressure in chronic uremia. Role of arterial wave reflections. Hypertension 1992;20:10-9.
58. Latham RD, Westerhof N, Sipkema P, et al. Regional wave travel and reflections along the human aorta: a study with six simultaneous micromanometric pressures. Circulation 1985;72:1257-69. (Pubitemid 16126806)
59. Baksi AJ, Treibel TA, Davies JE, et al. A meta-analysis of the mechanism of blood pressure change with aging. J Am Coll Cardiol 2009;54:2087-92.
60. Wang JJ, O'Brien AB, Shrive NG, et al. Time-domain representation of ventricular-arterial coupling as a windkessel and wave system. Am J Physiol Heart Circ Physiol 2003;284:H1358-68. (Pubitemid 36348600)
61. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46:200-4. (Pubitemid 40946514)
62. London GM, Guerin AP, Marchais SJ, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8. (Pubitemid 26274391)
63. Saeki A, Recchia F, Kass DA. Systolic flow augmentation in hearts ejecting into a model of stiff aging vasculature. Influence on myocardial perfusion-demand balance. Circ Res 1995;76:132-41.
64. Chen CH, Nakayama M, Nevo E, et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol 1998;32:1221-7.
65. Henry RM, Kamp O, Kostense PJ, et al. Mild renal insufficiency is associated with increased left ventricular mass in men, but not in women: an arterial stiffness-related phenomenon-the Hoorn Study. Kidney Int 2005;68:673-9. (Pubitemid 43323122)
66. Edwards NC, Hirth A, Ferro CJ, et al. Subclinical abnormalities of left ventricular myocardial deformation in early-stage chronic kidney disease: the precursor of uremic cardiomyopathy? J Am Soc Echocardiogr 2008;21:1293-8.
67. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005;45:494-501.
68. Chue CD, Townend JN, Steeds RP, et al. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010;96:817-23.
69. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45. (Pubitemid 39070505)
70. Schrier RW. Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol 2010;6:61.
71. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161-7. (Pubitemid 351159920)
72. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7. (Pubitemid 30094728)
73. Funder JW. Minireview: Aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology 2010;151:5098-102.
74. Del Vecchio L, Procaccio M, Vigano S, et al. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol 2007;3:42-9. (Pubitemid 46020702)
75. Luther JM, Luo P, Wang Z, et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int 2012 May 23. doi: 10.1038/ki.2012.170 [Epub ahead of print].
76. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009;54:505-12.
77. Edwards NC, Steeds RP, Chue CD, et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012;73:447-54.
78. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8. (Pubitemid 41725150)
79. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8. (Pubitemid 32880350)
80. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85. (Pubitemid 46762749)
81. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33. (Pubitemid 41532599)
82. Foley RN. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol 2009;4:1136-9.
83. KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009:113: S1-130.
84. Gutierrez OM. Increased serum phosphate and adverse clinical outcomes: unraveling mechanisms of disease. Curr Opin Nephrol Hypertens 2011;20:224-8.
85. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362:1312-24.
86. Torres PA, De Brauwere DP. Three feedback loops precisely regulating serum phosphate concentration. Kidney Int 2011;80:443-5.
87. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-84.
88. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-408.
89. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51. (Pubitemid 27494749)
90. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 2012;92:131-55.
91. Neves KR, Graciolli FG, dos Reis LM, et al. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:2237-44. (Pubitemid 41115286)
92. Chue CD, Edwards NC, Moody WE, et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 2012;98:219-24.
93. Li K, Kaaks R, Linseisen J, et al. Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg). Heart 2012;98:920-5.
94. Reid IR, Bolland MJ. Calcium supplements: bad for the heart? Heart 2012;98:895-6.
95. Limori S, Mori Y, Akita W, et al. Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clin Exp Nephrol 2012 May 12. [Epub ahead of print].
96. Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012;7:487-93.
97. Ferro CJ, Chue CD, Steeds RP, et al. Is lowering phosphate exposure the key to preventing arterial stiffening with age? Heart 2009;95:1770-2.